CDNA - CareDx, Inc
32.43
After hours: 4:08PM EDT
| Previous Close | 32.75 |
| Open | 32.62 |
| Bid | 30.10 x 800 |
| Ask | 32.41 x 800 |
| Day's Range | 31.57 - 32.72 |
| 52 Week Range | 10.31 - 39.38 |
| Volume | 643,875 |
| Avg. Volume | 948,395 |
| Market Cap | 1.366B |
| Beta (3Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | Aug 8, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.40 |
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of CDNA earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 CareDx Inc Earnings Call
- GlobeNewswire•6 days ago
CareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients
CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds the Department of Health and Human Services for releasing a report highlighting the cost savings of lifetime immunosuppressive drug coverage for transplant patients. CareDx is dedicated to improving the long-term health outcomes of transplant recipients. A critical part of protecting a donated kidney is appropriate dosage of immunosuppressant drugs for the life of the recipient, treatment financially out of reach for many individuals without insurance coverage.
- Motley Fool•11 days ago
Here's Why CareDx Stock Is Rising Today
The transplant diagnostic service provider took some important steps forward in the first quarter.
Motley Fool•12 days agoCareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript
CDNA earnings call for the period ending March 31, 2019.
- Zacks•12 days ago
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
CareDx (CDNA) delivered earnings and revenue surprises of 350.00% and 7.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•12 days ago
CareDx: 1Q Earnings Snapshot
On a per-share basis, the Brisbane, California-based company said it had a loss of 18 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The results ...
- GlobeNewswire•12 days ago
CareDx Reports First Quarter 2019 Results
BRISBANE, Calif., May 08, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire•13 days ago
CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019
BRISBANE, Calif., May 07, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.
- Simply Wall St.•14 days ago
The CareDx (NASDAQ:CDNA) Share Price Is Up 580% And Shareholders Are Delighted
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investing can be hard but the potential fo an individual stock to pay off big time inspires us...
- Insider Monkey•17 days ago
Hedge Funds Have Never Been This Bullish On CareDx, Inc. (CDNA)
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
- GlobeNewswire•17 days ago
AlloMap In-Network with Anthem Blue Cross
BRISBANE, Calif., May 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire•18 days ago
CareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care
CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced a partnership with Cibiltech, a French MedTech company that develops AI-based products for predictive medicine, to commercialize Predigraft. Predigraft is a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss. It was developed from Cibiltech’s proprietary software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients.
- Zacks•19 days ago
CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•25 days ago
CareDx Agrees to Acquire OTTR Complete Transplant Management
CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced it has agreed to acquire OTTR Complete Transplant Management (“OTTR”), the leading provider of organ transplant patient tracking software. OTTR provides comprehensive solutions for transplant patient management, which are currently used in over 60 leading transplant centers in the US.
- GlobeNewswire•27 days ago
CareDx to Announce First Quarter 2019 Financial Results on May 8th, 2019
BRISBANE, Calif., April 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients,.
- Simply Wall St.•last month
Breakeven On The Horizon For CareDx, Inc (NASDAQ:CDNA)
CareDx, Inc's (NASDAQ:CDNA): CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide...
- GlobeNewswire•last month
CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients
CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United States District Court for Delaware. In this suit, CareDx alleges that Natera’s comparisons of its kidney transplant technology to CareDx’s AlloSure technology are based on numerous unscientific, unreliable, and inappropriate conclusions, and are therefore misleading.
- GlobeNewswire•2 months ago
Cutting-Edge HeartCare and AlloMap Solutions Featured at ISHLT 2019
BRISBANE, Calif., April 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.
- TechCrunch•2 months ago
A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing
This morning, a publicly traded transplant diagnostics company called CareDx,along with Stanford University, sued another publicly traded genetic testingcompany, Natera, for patent infringement
- GlobeNewswire•2 months ago
CareDx Files Patent Infringement Lawsuit Against Natera
CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it has filed a patent infringement suit against Natera, Inc., in the United States District Court for Delaware. CareDx is asserting U.S. Patent Nos. 9,845,497 and 8,703,652, that are exclusively licensed to CareDx from Stanford University. Stanford is joined in the suit as a necessary party because it is the registered owner of these patents. These patents cover non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Cedars Sinai Uses AlloSure in Tocilizumab Trial
CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces a partnership with the Cedars-Sinai Comprehensive Transplant Center to study the use of AlloSure to characterize response to therapy in kidney transplant recipients that are being treated for chronic antibody-mediated rejection (ABMR). ABMR is recognized as the leading cause of late kidney transplant failure. Long-term graft survival has not improved, primarily due to late diagnosis and lack of effective therapeutic options.
- Simply Wall St.•2 months ago
These Factors Make CareDx, Inc (NASDAQ:CDNA) An Interesting Investment
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...
- Investor's Business Daily•2 months ago
Cisco Leads 5 Top Stocks Flexing Strength In Struggling Market
Cisco stock and Planet Fitness stock lead five top stocks showing relative strength amid the market pullback.
- GlobeNewswire•2 months ago
AlloSure Heart Clinical Validation Published in Leading Transplant Journal
BRISBANE, Calif., March 11, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.
